OBIO (Orchestra BioMed Holdings) Research & Development: $63.22 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OBIO Orchestra BioMed Holdings Inc OBIO
42 GF Score
Price $5.81
GF Value $31.57
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Orchestra BioMed Holdings Research & Development?

Orchestra BioMed Holdings OBIO +7.00% 42 Research & Development is $63.22 Mil as of Jun. 2026. GuruFocus rates OBIO with a GF Score™ of 42/100 and a GF Value™ of $31.57 (Possible Value Trap). The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Orchestra BioMed Holdings's Research & Development for the three months ended in Jun. 2026 was $16.59 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 was $63.22 Mil.

Orchestra BioMed Holdings  (NAS:OBIO) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Orchestra BioMed Holdings Research & Development Related Terms

Orchestra BioMed Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for Orchestra BioMed Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orchestra BioMed Holdings Research & Development Chart

Orchestra BioMed Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 12.89 21.95 33.82 42.80 58.19

Orchestra BioMed Holdings Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.85 14.03 16.82 15.78 16.59
OBIO
42GF Score
Orchestra BioMed Holdings Inc OBIO
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orchestra BioMed Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $63.22 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $63.22 Mil mean?
Orchestra BioMed Holdings (OBIO) has a Research & Development of $63.22 Mil as of Jun. 2026. Research and development expense is the total cost for research and development activities. View historical data on Orchestra BioMed Holdings and its competitors.
Is Orchestra BioMed Holdings' Research & Development too high?
Orchestra BioMed Holdings' current Research & Development is $63.22 Mil. Overall, Orchestra BioMed Holdings has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Orchestra BioMed Holdings' Research & Development compare to CYDY and IRD?
Orchestra BioMed Holdings' Research & Development of $63.22 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Orchestra BioMed Holdings and its competitors. Orchestra BioMed Holdings's current Research & Development is $63.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orchestra BioMed Holdings stock overvalued right now?
Based on GuruFocus' analysis, Orchestra BioMed Holdings (OBIO) is currently considered Possible Value Trap. The stock's GF Value™ is $31.57, compared to a current price of $5.81 — trading 81.6% below its estimated fair value. The current Research & Development is $63.22 Mil. Orchestra BioMed Holdings' overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Orchestra BioMed Holdings (OBIO), the current Research & Development is $63.22 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orchestra BioMed Holdings (OBIO) Overvalued in 2026?

Based on GuruFocus' analysis, Orchestra BioMed Holdings stock appears to be undervalued. The current stock price of $5.81 is trading 81.6% below its estimated GF Value™ of $31.57. GuruFocus considers Orchestra BioMed Holdings to be Possible Value Trap.

Key valuation signals for OBIO:

  • Research & Development: $63.22 Mil
  • GF Value™: $31.57 vs. price of $5.81 (81.6% below fair value)
  • GF Score™: 42/100 with 6 warning signs

No single metric tells the full story. See the OBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orchestra BioMed Holdings Business Description

Address 150 Union Square Drive, New Hope, PA, USA, 18938
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.
42GF Score

Get the complete analysis for OBIO

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.81
Price
$31.57
GF Value